Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Imaging experts debate link between CT scans, cancer risk

August 10, 2010
By Greg Frieherr
Greg Frieherr
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 8
Volume 19
Issue 8

Clinical studies examining the potential of CT exposure to cause cancer are under way, but it could be years or even a decade until the results are known, and even then, they may be inconclusive.

Clinical studies examining the potential of CT exposure to cause cancer are under way, but it could be years or even a decade until the results are known, and even then, they may be inconclusive.

A half dozen clinical studies are now enrolling hundreds of thousands of patients in Canada, the UK, Australia, Israel, Sweden, and France with the goal of looking specifically at whether CT is a cause of cancer. But the studies, mostly involving pediatric patients, will take many years to complete. And there is no guarantee the results will be definitive.

Andrew J. Einstein, MD, PhD, an assistant professor of clinical medicine in the departments of radiology and cardiology at New York's Columbia University, examined the current basis for concerns about radiation exposure from CT, noting that none of the data used to support these cautionary arguments involve CT radiation exposure itself. Instead they are largely drawn from studies examining survivors of the atomic bombing of Hiroshima, nuclear industry workers, and exposure of children to radiation in utero. "But it is still important that we do such studies because each additional study provides us with new information and a more complete picture of the issues that we are dealing with," Dr. Einstein said.


ANDREW J. EINSTEIN, MD, PHD

In the meantime, the CT community and the public will be left with only circumstantial data to make or break the connection between CT exams and cancer, a prospect that concerns Cynthia H. McCollough, PhD, director of the CT Clinical Innovation Center at the Mayo Clinic College of Medicine in Rochester, Minn.

Some patients are making poor decisions about their healthcare because of their unjustified fear of CT radiation, Dr. McCollough said, promulgated by data with considerable uncertainty. Despite 60 years of studying the A-bomb survivors, for example, no definitive conclusions have yet been made about the cancer risk at the relatively low doses commonly encountered during CT studies.

"When people say we just don't know what's happening, I disagree," she said. "We know that it is not a big effect. If it is an effect at all, it is a really small effect."

Dr. McCollough has a simple solution to the debate over radiation dose and CT, as it relates to deciding whether to schedule an exam. "If the CT is needed, do it, and do it carefully," she said. "And if it's not needed, don't do it."

References:

Source: 2010 International Symposium for Multidetector CT, International Society for Computed Tomography.

Articles in this issue

Colorectal cancer patients with vitamin D deficiency see worse outcomes
What is the Clinical Role of Induction Therapy in Locally Advanced Squamous Cell Cancer of the Head and Neck?
What is the Clinical Role of Induction Therapy in Locally Advanced Squamous Cell Cancer of the Head and Neck?
Who's News
Sonography better to monitor small testicular lesions
FDA Panel Says No More Avastin in Breast Cancer
Cell-signaling pathway may be new Rx target ER+ breast cancer
Evidence-based pathway plus electronic health records system matches major trials for colorectal cancer treatment outcomes
Ohio cancer center breaks ground on $1 billion addition
Second-Generation TKIs Poised to Succeed Imatinib in Newly Diagnosed CML
Imaging experts debate link between CT scans, cancer risk
From the ONI archives: CML patients’ molecular response to nilotinib continues to deepen over time
Smartphones hustle to maintain pace with rapid rate of change in oncology
Making comparative effectiveness work in cancer care
Geriatric assessment, communication skills essential for older patients
Patients look for answers on Web but trust it less
Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
1 expert is featured in this series.
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
Related Content
Advertisement

The drug that the companion diagnostic identifies patients for, zongertinib, received FDA approval for HER2-mutant NSCLC on August 8, 2025.

FDA Approves NGS-Based Companion Diagnostic for Zongertinib in NSCLC

Roman Fabbricatore
August 12th 2025
Article

The drug that the companion diagnostic identifies patients for, zongertinib, received FDA approval for HER2-mutant NSCLC on August 8, 2025.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


Obesity and weight gain are associated with adverse outcomes following breast cancer diagnosis.

GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer

Sherry Shen, MD;Bethina Liu, MD;Chad Fanti, MD;Maria Bromberg, MPH;Yuan Chen, PhD;Cassandra Chang;Neil M. Iyengar, MD
August 12th 2025
Article

Patients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.


Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.


Findings demonstrate a need to move beyond disease-related factors to address disparities in HMA treatment patterns among those with MDS.

Data Show Disparities in HMA Use Among Myelodysplastic Syndrome Populations

Russ Conroy
August 11th 2025
Article

Findings demonstrate a need to move beyond disease-related factors to address disparities in HMA treatment patterns among those with MDS.


The decision is based on phase 3 VERITAC-2 trial data showing a significant PFS improvement vs fulvestrant in ESR1-mutant ER+/HER2– breast cancer.

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2– Breast Cancer

Roman Fabbricatore
August 11th 2025
Article

The decision is based on phase 3 VERITAC-2 trial data showing a significant PFS improvement vs fulvestrant in ESR1-mutant ER+/HER2– breast cancer.

Related Content
Advertisement

The drug that the companion diagnostic identifies patients for, zongertinib, received FDA approval for HER2-mutant NSCLC on August 8, 2025.

FDA Approves NGS-Based Companion Diagnostic for Zongertinib in NSCLC

Roman Fabbricatore
August 12th 2025
Article

The drug that the companion diagnostic identifies patients for, zongertinib, received FDA approval for HER2-mutant NSCLC on August 8, 2025.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


Obesity and weight gain are associated with adverse outcomes following breast cancer diagnosis.

GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer

Sherry Shen, MD;Bethina Liu, MD;Chad Fanti, MD;Maria Bromberg, MPH;Yuan Chen, PhD;Cassandra Chang;Neil M. Iyengar, MD
August 12th 2025
Article

Patients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.


Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.


Findings demonstrate a need to move beyond disease-related factors to address disparities in HMA treatment patterns among those with MDS.

Data Show Disparities in HMA Use Among Myelodysplastic Syndrome Populations

Russ Conroy
August 11th 2025
Article

Findings demonstrate a need to move beyond disease-related factors to address disparities in HMA treatment patterns among those with MDS.


The decision is based on phase 3 VERITAC-2 trial data showing a significant PFS improvement vs fulvestrant in ESR1-mutant ER+/HER2– breast cancer.

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2– Breast Cancer

Roman Fabbricatore
August 11th 2025
Article

The decision is based on phase 3 VERITAC-2 trial data showing a significant PFS improvement vs fulvestrant in ESR1-mutant ER+/HER2– breast cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.